Gabapentin Capsule
Product Images NDC 50090-7421

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7421). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Equation)

A formula for calculating creatinine clearance (CLCr), involving age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Fig 1 (Fig 1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over an 8-week period for Placebo and Gabapentin 3600 mg/day. The graph shows two periods: a 4-week dose titration followed by a 4-week fixed dose period, with pain scores decreasing more in the Gabapentin group across weeks compared to Placebo.*

FDA Label Image

Fig 2 (Fig 2)

A line graph displaying weekly mean pain scores over seven weeks in a clinical study population. The x-axis represents weeks from baseline to week 7, and the y-axis measures mean pain score from 0 to 10. Three lines compare placebo with gabapentin at 1800 mg/day and 2400 mg/day dosages, showing pain score trends over time.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart comparing the proportion of responders with at least 50% reduction in pain score at the endpoint in controlled postherpetic neuralgia (PHN) studies. It shows results from two studies: Study 1 compares placebo (PBO) at 12% versus gabapentin (GBP) 3600 mg at 29%, and Study 2 compares placebo (PBO) at 14% versus gabapentin (GBP) 1800 mg at 32% and 2400 mg at 34%. Statistical significance is indicated with p values less than 0.01 and 0.001.*

FDA Label Image

Fig 4 (Fig 4)

A bar chart showing responder rates in patients receiving gabapentin compared to placebo by daily dose (600 mg, 900 mg, 1200 mg, 1800 mg) across three separate studies labeled as STUDY a, STUDY b, and STUDY c. The y-axis represents difference in responder rate as a percentage, ranging from 2% to 22%. Different symbols distinguish the three studies on the chart.*

FDA Label Image

Structure (Struct)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). The diagram depicts the molecular arrangement of the active ingredient gabapentin.*

FDA Label Image

Label Image (Lbl500907421)

Label for GABAPENTIN 300 mg capsules by A-S Medication Solutions. The label shows the product name, dosage strength of 300 mg per capsule, oral capsule form, and package count of 90 capsules. Storage instructions specify to store at 77 degrees Fahrenheit. The label also includes NDC 50090-7421-0 and packaging location in Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.